Save 70% on Feiba today! Same manufacturing site as US Feiba.
Non-english packaging is often present for European medicines- English label and English insert included. Plan in advance - allow us 7 days to ship this brand name medicine.
According to the European Medicines Agency, brand name Feiba originating from Europe is manufactured at the following site(s):Takeda Manufacturing Austria AG Industriestraße 67 1221 Vienna Austria
Information about Feiba (Anti-inhibitor Coagulant Complex)
Feiba is a hemostatic agent used to control bleeding in patients with hemophilia A or B who have developed inhibitors against factor VIII or IX. It contains activated prothrombin complex and works by bypassing the need for these factors in the coagulation cascade.
Product Highlights
- Specifically indicated for the management of bleeding in patients with hemophilia A or B with inhibitors.
Key Ingredient
- Anti-inhibitor coagulant complex
Key Benefits
- Rapidly helps to achieve hemostasis during bleeding episodes.
- Effective for patients with inhibitors who cannot use conventional factor replacement therapies.
- Can be administered at home under proper guidance, enhancing patient autonomy.
Direction of Use
- Feiba should be reconstituted according to the manufacturer’s instructions and administered via slow intravenous injection.
- Dosage and frequency depend on the clinical situation and physician guidance.
Safety Concerns
- Fever, headache, injection site reactions, and nausea.
- Potential for thrombosis or thromboembolic events due to the increased levels of activated coagulation factors.
- Patients may require regular monitoring of coagulation parameters and overall clinical status.
Avoid Feiba (Anti-inhibitor Coagulant Complex) If
- You have a known hypersensitivity to any component of Feiba.
- You have a history of thrombosis or thromboembolic disorders.
- You are experiencing active bleeding from a source that requires surgical intervention rather than medical management.
